 SIOUX FALLS, S.D.--BUSINESS WIRE--- BCYP BCYP--SAB Biotherapeutics SAB, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibody therapeutics without the need for human donors, today announced the publication of data showing that SAB-185, the companys therapeutic candidate for the treatment of COVID-19 infections, demonstrates effective and potent neutralization of multiple SARS-CoV-2 variants of co 